Latest News

Novartis Gene Therapies SMA Community Update

October 5, 2023
Posted in ,

Dear SMA Community, It was a pleasure to be able to join so many of you at the Cure SMA Annual Conference in Orlando this year, and we look forward […]

Read More ›

Cure SMA on Capitol Hill – A Message from Allie Williams

October 4, 2023
Posted in ,

Hey, it’s Allie here from Oklahoma! I am privileged to serve on the Cure SMA Adult Advisory Council and am part of a group of adults and family members with […]

Read More ›

SMA Highlights and Updates from Biogen

October 2, 2023
Posted in ,

Dear SMA Community, As we reflect on SMA Awareness Month, we take this opportunity to celebrate all those who are a part of the SMA community and the future we’re […]

Read More ›

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

September 28, 2023
Posted in ,

An important part of Cure SMA’s core mission is to carry out and support research that will improve the quality of life for all people with SMA. We recently published […]

Read More ›

NMD Pharma Initiates Phase II Trial for SMA

September 26, 2023
Posted in , ,

NMD Pharma, a clinical-stage biotech company leading the development of novel first-in-class therapies for severe neuromuscular disorders, recently announced that the first SMA patient has been dosed in their Phase […]

Read More ›

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

September 19, 2023
Posted in , ,

Today, Scholar Rock announced that enrollment in their Phase 3 SAPPHIRE trial is now complete. The Phase 3 trial will evaluate the safety and efficacy of apitegromab in nonambulatory patients with […]

Read More ›
Scroll to Top